0001493152-23-022532.txt : 20230626 0001493152-23-022532.hdr.sgml : 20230626 20230626172517 ACCESSION NUMBER: 0001493152-23-022532 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230623 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230626 DATE AS OF CHANGE: 20230626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRxADE HEALTH, INC CENTRAL INDEX KEY: 0001382574 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39199 FILM NUMBER: 231043310 BUSINESS ADDRESS: STREET 1: 2420 BRUNELLO TRACE CITY: LUTZ STATE: FL ZIP: 33558 BUSINESS PHONE: (800) 261 0281 MAIL ADDRESS: STREET 1: 2420 BRUNELLO TRACE CITY: LUTZ STATE: FL ZIP: 33558 FORMER COMPANY: FORMER CONFORMED NAME: TRXADE GROUP, INC. DATE OF NAME CHANGE: 20140207 FORMER COMPANY: FORMER CONFORMED NAME: XCELLINK INTERNATIONAL INC. DATE OF NAME CHANGE: 20081230 FORMER COMPANY: FORMER CONFORMED NAME: Bluebird Exploration Co. DATE OF NAME CHANGE: 20061204 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 23, 2023

TRxADE HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39199

46-3673928

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2420 Brunello Trace, Lutz, Florida		33558
(Address of principal executive offices)		(Zip Code)

(800) 261-0281

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.00001 per share		MEDS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On June 23, 2023, the Listing Qualifications department of The Nasdaq Stock Market LLC (the “Nasdaq”) notified the Company that the Company was not in compliance with Nasdaq’s listing rules (the “Listing Rules”) as set forth in Listing Rule 5550(a)(4) given the Company’s failure to maintain a sufficient number of publicly held shares (the “Notice”). Citing the Company’s Event Form submitted to Nasdaq on June 7, 2023, Nasdaq calculated the Company’s publicly held shares as approximately 310,057 (which amount excludes shares held by officers, directors, or beneficial owners of 10 percent or more), on a post-split basis, effective as of June 22, 2023. To satisfy the requirement for continued listing on Nasdaq, the Company must maintain a minimum of 500,000 publicly held shares.

The Notice states that the Company has until August 7, 2023 to submit a plan to regain compliance with Listing Rule 5550(a)(4). If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On June 26, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of the Series B Preferred Stock with the Secretary of State of the State of Delaware (the “Certificate of Designation”). The Certificate of Designation provides for the issuance of shares of the Company’s Series B Preferred Stock, par value $0.00001 per share (the “Series B Preferred Stock”).

Pursuant to the Certificate of Designation, the Series B Preferred Stock is non-participating and shall receive no dividends, has no liquidation preference, has no voting rights, and has no redemption rights.

The Series B Preferred Stock is not convertible at the election of the holder. Upon approval of conversion by the Company’s stockholders, each outstanding share of Series B Preferred Stock (including any fraction of a share) shall automatically convert into 100 shares of the Company’s common stock, par value $0.00001 per share, without any further action by the relevant holder of such Series B Preferred Stock or the Company.

In the event that a merger, acquisition of reorganization of the Company or its subsidiary with Superlatus, Inc., as previously disclosed in the Current Report on Form 8-K filed by the Company on June 23, 2023 does not close before December 31, 2023, the Company will repurchase all of the shares of Series B Preferred Stock for the price originally paid by each holder for the Series B Preferred Stock.

The foregoing description of the Certificate of Designation is a summary and is qualified in its entirety by the terms of the Certificate of Designation filed with the Secretary of State of the State of Delaware, which is attached hereto as Exhibit 3.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

Exhibit No.		Description of Exhibit
3.1		Certificate of Designation of Series B Preferred Stock
104		Inline XBRL for the cover page of this Current Report on Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TRxADE HEALTH, INC.

	By:	/s/ Suren Ajjarapu
	Name:	Suren Ajjarapu
	Title:	Chief Executive Officer

Dated: June 26, 2023

EX-3.1 2 ex3-1.htm

Exhibit 3.1

TRxADE HEALTH, INC.

CERTIFICATE OF DESIGNATION OF PREFERENCES,

RIGHTS AND LIMITATIONS

OF

SERIES B PREFERRED STOCK

Pursuant to Section 151 of the General Corporation Law of the State of Delaware, TRxADE HEALTH, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 103 thereof, does hereby submit the following:

WHEREAS, the Second Amended and Restated Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”) authorizes the issuance of up to 10,000,000 shares of preferred stock, par value $0.00001 per share, of the Corporation (“Preferred Stock”) in one or more series, and expressly authorizes the Board of Directors of the Corporation (the “Board”), subject to limitations prescribed by law, to provide, out of the unissued shares of Preferred Stock, for series of Preferred Stock, and, with respect to each such series, to establish and fix the number of shares to be included in any series of Preferred Stock and the designation, rights, preferences, powers, restrictions, and limitations of the shares of such series; and

WHEREAS it is the desire of the Board to establish and fix the number of shares to be included in a new series of Preferred Stock and the designation, rights, preferences, and limitations of the shares of such new series.

NOW, THEREFORE, BE IT RESOLVED, that the Board does hereby provide for the issue of a series of Preferred Stock and does hereby in this Certificate of Designation (the “Certificate of Designation”) establish and fix and herein state and express the designation, rights, preferences, powers, restrictions, and limitations of such series of Preferred Stock as follows:

1. Designation. There shall be a series of Preferred Stock that shall be designated as “Series B Preferred Stock” (the “Series B Preferred Stock”) and the number of Shares constituting such series shall be 787,754. The rights, preferences, powers, restrictions, and limitations of the Series B Preferred Stock shall be as set forth herein.

2. Defined Terms. For purposes hereof, the following terms shall have the following meanings:

“Board” has the meaning set forth in the Recitals.

“Certificate of Designation” has the meaning set forth in the Recitals.

“Certificate of Incorporation” has the meaning set forth in the Recitals.

“Common Stock” means the common stock, par value $0.00001 per share, of the Corporation.

“Corporation” has the meaning set forth in the Preamble.

“Merger Transaction” means a merger, acquisition or reorganization of the Corporation or its Subsidiary with Superlatus, Inc.

“Merger Transaction Closing” means the closing of the Merger Transaction.

“Original Purchase Price” means the price paid by each holder for the Series B Preferred Stock.

1

“Person” means an individual, corporation, partnership, joint venture, limited liability company, governmental authority, unincorporated organization, trust, association, or other entity.

“Preferred Stock” has the meaning set forth in the Recitals.

“Securities Act” means the Securities Act of 1933, as amended, or any successor federal statute, and the rules and regulations thereunder, which shall be in effect at the time.

“Share” means a share of Series B Preferred Stock.

“Subsidiary” means, with respect to any Person, any other Person of which a majority of the outstanding shares or other equity interests having the power to vote for directors or comparable managers are owned, directly or indirectly, by the first Person.

3. Dividends. The Series B Preferred Stock shall be non-participating and receive no dividends.

4. Liquidation. The Series B Preferred shall have no liquidation preference.

5. Voting. The Series B Preferred Stock shall have no voting rights.

6. Redemption. The Series B Preferred Stock shall have no redemption rights.

7. Conversion.

7.1 Automatic Conversion. The Series B Preferred Stock is not convertible at the election of the holder. Upon approval of conversion by the Corporation’s stockholders, each outstanding Share of Series B Preferred Stock (including any fraction of a Share) shall automatically convert into 100 shares of Common Stock.

7.2 Procedures for Conversion; Effect of Conversion.

(a) Procedures for Automatic Conversion. Upon approval of conversion by the Corporation’s stockholders, all outstanding Shares of Series B Preferred Stock shall be converted into Common Stock, without any further action by the relevant holder of such Shares or the Corporation. All shares of Common Stock issued hereunder by the Corporation shall be duly and validly issued, fully paid, and nonassessable, free and clear of all taxes, liens, charges, and encumbrances with respect to the issuance thereof.

(b) Effect of Conversion. All Shares of Series B Preferred Stock converted as provided in this Section 7.2 shall no longer be deemed outstanding as of the effective time of the applicable conversion and all rights with respect to such Shares shall immediately cease and terminate as of such time, other than the right of the holder to receive shares of Common Stock in exchange therefor.

7.3 Reservation of Stock. The Corporation shall at all times when any Shares of Series B Preferred Stock are outstanding reserve and keep available out of its authorized but unissued shares of capital stock, solely for the purpose of issuance upon the conversion of the Series B Preferred Stock, such number of shares of Common Stock issuable upon the conversion of all outstanding Series B Preferred Stock pursuant to this Section 7. The Corporation shall take all such actions as may be necessary to assure that all such shares of Common Stock may be so issued without violation of any applicable law or governmental regulation or any requirements of any domestic securities exchange upon which shares of Common Stock may be listed (except for official notice of issuance which shall be immediately delivered by the Corporation upon each such issuance). The Corporation shall not close its books against the transfer of any of its capital stock in any manner which would prevent the timely conversion of the Shares of Series B Preferred Stock.

2

7.4 No Charge or Payment. The issuance of shares of Common Stock upon conversion of Shares of Series B Preferred Stock pursuant to Section 7.1 shall be made without payment of additional consideration by, or other charge, cost, or tax to, the holder in respect thereof.

7.5 Termination of Conversion Rights. In the event that the Merger Transaction Closing does not occur by December 31, 2023, the Corporation will repurchase all of the Shares of Series B Preferred for the Original Purchase Price paid by each holder.

8. Reissuance of Series B Preferred Stock. Any Shares of Series B Preferred Stock converted, or otherwise acquired by the Corporation or any Subsidiary shall be cancelled and retired as authorized and issued shares of capital stock of the Corporation.

9. Notices. Except as otherwise provided herein, all notices, requests, consents, claims, demands, waivers, and other communications hereunder shall be in writing and shall be deemed to have been given: (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent (a) to the Corporation, at its principal executive offices and (b) to any stockholder, at such holder’s address at it appears in the stock records of the Corporation (or at such other address for a stockholder as shall be specified in a notice given in accordance with this Section 9).

10. Amendment and Waiver. No provision of this Certificate of Designation may be amended, modified, or waived except by an instrument in writing executed by the Corporation and each holder of Series B Preferred Stock.

[signature page follows]

3

IN WITNESS WHEREOF, this Certificate of Designation is executed on behalf of the Corporation by its Chief Executive Officer as of June 26, 2023.

	TRxADE HEALTH, INC.

	By:	/s/ Surendra Ajjarapu
		Surendra Ajjarapu
		Chief Executive Officer

[Signature Page to Series B Preferred Stock Certificate of Designation]

EX-101.SCH 3 meds-20230623.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 meds-20230623_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 meds-20230623_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 23, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 23, 2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-39199
Entity Registrant Name	TRxADE HEALTH, INC.
Entity Central Index Key	0001382574
Entity Tax Identification Number	46-3673928
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2420 Brunello Trace
Entity Address, City or Town	Lutz
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33558
City Area Code	(800)
Local Phone Number	261-0281
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.00001 per share
Trading Symbol	MEDS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001382574 2023-06-23 2023-06-23 iso4217:USD shares iso4217:USD shares 0001382574 false --12-31 8-K 2023-06-23 TRxADE HEALTH, INC. DE 001-39199 46-3673928 2420 Brunello Trace Lutz FL 33558 (800) 261-0281 false false false false Common Stock, par value $0.00001 per share MEDS NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://trxadehealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex3-1.htm meds-20230623.xsd meds-20230623_lab.xml meds-20230623_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "meds-20230623_lab.xml" ] }, "presentationLink": { "local": [ "meds-20230623_pre.xml" ] }, "schema": { "local": [ "meds-20230623.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MEDS", "nsuri": "http://trxadehealth.com/20230623", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-06-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://trxadehealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-06-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://trxadehealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001493152-23-022532-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-022532-xbrl.zip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end